May 21, 2026 05:00PM
May 19, 2026 08:00AM
May 19, 2026 08:00AM
May 5, 2026 04:05PM
Feb 10, 2026 04:05PM
Feb 4, 2026 07:08AM
Feb 2, 2026 08:03AM FDA accepts Exelixis drug application for colorectal cancer treatment
Feb 2, 2026 08:00AM
Mar 26, 2025 01:08PM
Mar 26, 2025 01:07PM
Feb 11, 2025 04:05PM
Jan 24, 2025 02:31PM
Jan 24, 2025 02:30PM
Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA
Jan 12, 2025 04:00PM
Jan 9, 2025 09:00AM
Nov 27, 2024 07:08AM
Nov 26, 2024 04:05PM
Oct 29, 2024 04:05PM
Oct 16, 2024 06:54AM
Oct 16, 2024 06:03AM Goldman Sachs Reiterates Sell Rating on Exelixis (EXEL)
Sep 16, 2024 02:01PM
Sep 16, 2024 08:45AM
Sep 16, 2024 08:45AM
Aug 6, 2024 04:05PM
Aug 6, 2024 08:30AM
Aug 6, 2024 08:30AM
Feb 14, 2024 08:30AM Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
Nov 2, 2021 04:05PM
Sep 20, 2021 11:30AM
Sep 20, 2021 11:30AM
Sep 17, 2021 04:24PM
Sep 17, 2021 04:23PM
Aug 5, 2021 04:05PM
Aug 5, 2021 08:01AM Exelixis (EXEL) Announces FDA Accepts for Priority Review sNDA for CABOMETYX for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Aug 5, 2021 08:00AM
Apr 29, 2021 06:59AM
Jan 22, 2021 01:10PM
Jan 10, 2021 04:00PM
Nov 5, 2020 04:05PM
Nov 5, 2020 06:59AM
Oct 19, 2020 07:00AM Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review Applications for OPDIVO in Combination with CABOMETYX in Advanced Renal Cell Carcinoma
Oct 19, 2020 06:59AM
Dec 5, 2018 01:33AM
Nov 15, 2018 01:32AM
Nov 1, 2018 04:05PM
Oct 22, 2018 06:50AM
Oct 22, 2018 06:45AM
Oct 22, 2018 06:17AM Exelixis (EXEL) Highlights Results from Two Analyses Evaluating Effect of PD-L1 Expression or Prior Treatment with Checkpoint Inhibitors on Efficacy of Cabozantinib
Oct 20, 2018 08:45AM

15,464 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All